Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Temozolomide for recurrent high-grade glioma.

D R Macdonald1

  • 1Department of Oncology, University of Western Ontario, London Regional Cancer Centre, London, Ontario, Canada.

Seminars in Oncology
|September 11, 2001
PubMed
Summary

Temozolomide offers a new oral treatment for high-grade gliomas, improving survival and quality of life. This chemotherapy agent shows efficacy in recurrent malignant glioma, providing a valuable therapeutic option.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.

Neurology·2011
Same author

Neurocytomas: long-term experience of a single institution.

Neuro-oncology·2011
Same author

Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas.

The Lancet. Oncology·2011
Same author

Infective Hepatitis Treated with Glucose, Insulin, and Ascorbic Acid.

British medical journal·2010
Same author

Low-grade gliomas in children: tumor volume response to radiation.

Neurosurgical focus·2006
Same author

Results of a policy of surveillance alone after surgical management of pediatric low grade gliomas.

International journal of radiation oncology, biology, physics·2001

Area of Science:

  • Neuro-oncology
  • Medical oncology
  • Clinical pharmacology

Background:

  • High-grade malignant gliomas, including anaplastic astrocytoma and glioblastoma multiforme, have a poor prognosis despite aggressive treatments.
  • Tumor recurrence is common, and existing therapies offer limited enduring responses and negatively impact patient quality of life.
  • Novel therapeutic strategies are essential to enhance symptom control, improve quality of life, and extend progression-free and overall survival.

Purpose of the Study:

  • To evaluate the efficacy and safety of temozolomide, a novel oral antineoplastic agent, in patients with high-grade gliomas.
  • To compare temozolomide with procarbazine in patients with glioblastoma multiforme regarding survival and quality of life.
  • To assess the response rate and quality of life in patients with relapsed anaplastic astrocytoma treated with temozolomide.

Main Methods:

  • A pivotal randomized international phase II trial compared temozolomide (n=112) with procarbazine (n=113) in glioblastoma multiforme patients.
  • A large multicenter single-arm trial (N=162) evaluated temozolomide in patients with relapsed anaplastic astrocytoma.
  • Quality of life was assessed using the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire and brain-cancer-specific symptoms.

Main Results:

  • Temozolomide significantly improved median and 6-month progression-free survival and 6-month overall survival compared to procarbazine in glioblastoma multiforme.
  • Patients receiving temozolomide demonstrated superior responses in all seven tested quality-of-life domains.
  • Temozolomide showed an impressive response rate in relapsed anaplastic astrocytoma, with patients maintaining or improving quality of life.

Conclusions:

  • Temozolomide is an effective oral chemotherapy agent for high-grade gliomas, offering improved survival outcomes.
  • The drug provides significant benefits in quality of life for patients with glioblastoma multiforme and anaplastic astrocytoma.
  • Temozolomide presents a valuable therapeutic option for recurrent malignant glioma, characterized by a predictable safety profile, clinical efficacy, and convenient administration.

Related Experiment Videos